Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study

IntroductionEffective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to com...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ting Hu, Fang Zhou, Yang Zheng, Bohan Luo, Yongliang Zhang, Chengpeng Gu, Guopeng Wang, Jinze Zhang, Jingzhi Tian, Yu Nie, Yunlin Feng, Shangqing Ren, Wenjia Di, Dong Wang
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-06-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	metastatic hormone-sensitive prostate cancer darolutamide abiraterone acetate androgen deprivation therapy efficacy safety
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1608339/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!